| Imagery Source: Bausch Health Companies Inc |
| Information Source: Bausch Health Companies Inc |
- First Quarter Consolidated Revenues of $2.26 billion, up 5% on a reported basis and 6% on an Organic (non-GAAP)1 basis over the prior year period
|
- GAAP Net Loss Attributable to Bausch Health Companies of $58 million and GAAP Net Loss of $86 million
|
- Consolidated Adjusted EBITDA Attributable to Bausch Health Companies (non-GAAP)1 of $661 million, in line with the prior year period.
|
| BAUSCH HEALTH EXCLUDING BAUSCH + LOMB FIRST QUARTER 2025 RESULTS |
- Eighth consecutive quarter of year-over-year Revenue and Adjusted EBITDA (non-GAAP)1 growth, with 6% and 14% growth versus the prior year period, respectively
|
- With strong financial momentum, we remain committed to evaluating all options to unlock shareholder value, including maximising the value of assets and share buybacks.
|
- Completed $7.9B refinancing in early April to extend near- and medium-term maturities
|
- Receivedaa favourable ruling from the D.C. District Court in Norwich's case against the FDA
|
- Maintaining full-year 2025 Revenue and Adjusted EBITDA (non-GAAP)1 guidance, with Adjusted Cash Flow from Operations (non-GAAP)1 guidance updated primarily to reflect higher interest expense
|
| Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC) ("Bausch Health" or the "Company" or "we" or "our") today announced its first quarter 2025 financial results and other key updates from the quarter. |
| "We started the year strong, delivering our eighth consecutive quarter of year-over-year growth in Revenue and adjusted EBITDA for Bausch Health, excluding Bausch + Lomb, highlighting the broad momentum across our diverse businesses and geographies. Alongside our healthy financial and operating performance, in early April, we successfully closed a comprehensive refinancing transaction, delivering on our commitment to continue to improve our capital structure and maturity profile. We are laser-focused on growing profitably and executing against our strategic priorities, including evaluating all options to unlock shareholder value," said Thomas J. Appio, Chief Executive Officer, Bausch Health. |
| First Quarter 2025 Revenue Performance |
| Total consolidated reported revenues were $2.26 billion for the first quarter of 2025, compared with $2.15 billion in the first quarter of 2024, an increase of $106 million, or 5%. Excluding the impact of foreign exchange of $37 million, acquisitions of $6 million, and divestitures and discontinuation, which negatively impacted the prior year by $8 million, revenue increased 6% on an organic1 basis compared with the first quarter of 2024. |
| For the full document, click the link below |
| Bausch Health Companies Inc |
| Stay ahead of the curve! Subscribe to InsidEntity for daily updates on all your favourite companies. |
